. Author manuscript; available in PMC: 2010 Jul 13.

Published in final edited form as: Arch Intern Med. 2009 Jul 13;169(13):1195–1202. doi: 10.1001/archinternmed.2009.175

Table 3.

Change in 3MSE (points per year of exposure to ACE inhibitors) ^a

	Unadjusted			Adjusted^b

	3MSE	SE	P Value^c	3MSE	SE	P Value^c
Other Antihypertensive Drugs (reference)	−0.49	0.07		−0.45	0.06
ACE inhibitors (all)	−0.32	0.11	0.15	−0.28	0.09	0.09
Centrally Active ACE inhibitors	−0.22	0.13	0.06	−0.16	0.11	0.01
Non-Centrally Active ACE inhibitors	−0.52	0.17	0.83	−0.53	0.15	0.60

In separate models we examined all ACE inhibitors versus reference and centrally versus non-centrally active versus reference. The reference group was the same in both models.

Adjusted for age, sex, race, education, income, smoking, alcohol use, diabetes, coronary artery disease, serum creatinine, serum low density lipoprotein at baseline as well as depression scores, systolic blood pressure, stroke, and other hypertension drug use annually.

The P values listed reflect a comparison with the reference group.